Journal
CURRENT GENOMICS
Volume 12, Issue 8, Pages 626-631Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138920211798120808
Keywords
Anaplastic thyroid cancer; targeted molecular therapies; tyrosine kinase inhibitors; aurora kinase inhibitors; peroxisome proliferator-activated receptor-gamma; RET; BRAF; VEGFR
Ask authors/readers for more resources
The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (BRAF V600E, RET/PTC) or signaling kinases [vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR)] involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies (sorafenib, sunitinib, axitinib, imanitib, vandetanib, pazopanib, gefitinib) in stabilizing the course of the disease. Until now, however, no consensus guidelines have been established for patient selection and more data on toxicities and side effects are needed to be collected.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available